E2F6 is a transcriptional repressor belonging to the inhibitor subclass of E2F family proteins that lacks transcriptional activation and pocket protein binding domains 1. E2F6 functions as an inhibitor of E2F-dependent transcription by binding DNA cooperatively with DP proteins through E2 recognition sites, with preference for 5'-TTTCCCGC-3' sequences 1. Mechanistically, E2F6 appears to regulate cell cycle entry by repressing expression of E2F-dependent genes required for cell cycle initiation but not progression 1. E2F6 also represses meiosis-specific genes, and its mRNA is destabilized by MEIOC-YTHDC2-RBM46 complex during spermatogenesis, leading to derepression of meiosis-associated genes including Meiosin 2. E2F6 forms complexes with Polycomb proteins SUZ12 and EZH2, which may modulate its repressive activity 3. Disease relevance includes roles in cancer progression, where E2F6 can facilitate immune escape in esophageal cancer through the LINC01592/E2F6/NBR1/MHC-I axis 4 and serves as a prognostic biomarker across multiple cancer types 5. Clinically, E2F6 expression correlates with cancer prognosis and immunotherapy responses, suggesting potential therapeutic targeting applications 5.